Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, Fla.
Department of Political Science and Economics, Rowan University, Glassboro, NJ.
J Vasc Surg. 2021 Dec;74(6):1861-1866.e1. doi: 10.1016/j.jvs.2021.05.050. Epub 2021 Jun 26.
Significant debate exists among providers who perform endovascular abdominal aortic aneurysm repair (EVAR) regarding the renal function change between suprarenal (SuF) and infrarenal (InF) fixation devices. The purpose of this study is to review our institution's experience using these devices in terms of renal function.
This is a retrospective review of all elective EVARs performed within a three-site health system (Florida, Minnesota, and Arizona) during the period of 2000 to 2018. The primary outcome was renal function decline on long-term follow-up depending on the anatomical fixation of the device (SuF vs InF). Secondary outcomes were length of hospitalization (LOH) and progression to hemodialysis. Multivariable regression analysis was performed to test for associations affecting LOH.
There were 1130 elective EVARs included in our review. Of those, 670 (59.3%) had SuF and 460 (40.7%) InF. Long-term follow-up was 4.8 ± 3.7 years, and the rate of change in creatinine and estimated glomerular filtration rate (eGFR) were not statistically significant among groups (SuF vs InF). LOH was higher in those individuals with a SuF device (3.4 ± 2.2 vs 2.3 ± 1.0 days; P < .001). Ten patients with chronic kidney disease progressed to hemodialysis at 6.7 ± 3.8 years from EVAR. On Kaplan-Meier analysis, patients with chronic kidney disease with SuF were more likely to progress to hemodialysis (P = .039). On multivariable regression, female sex (Coef, 2.4; 95% confidence interval [CI], 0.17-0.41; P = .02), SuF (Coef, 9.5; 95% CI, 0.11-1.11; P < .0001), and intraoperative blood loss of greater than 150 mL (Coef, 15.4; 95% CI, 0.11-1.76; P < .0001) were predictors of prolonged LOH.
Our three-site, single-institution data indicate that, although the starting eGFR was statistically lower in those individuals undergoing elective EVAR with InF, device fixation type did not affect the creatinine and eGFR on long-term follow-up. However, caution should be exercised at the time of abdominal aortic aneurysm repair in those individuals who already presented with renal dysfunction.
在进行血管内腹主动脉瘤修复(EVAR)的医生中,对于肾上(SuF)和肾下(InF)固定装置之间肾功能变化存在显著争议。本研究的目的是回顾我们机构在使用这些装置方面的经验,评估其对肾功能的影响。
这是对 2000 年至 2018 年期间在一个三站点医疗系统(佛罗里达州、明尼苏达州和亚利桑那州)中进行的所有择期 EVAR 的回顾性研究。主要结局是根据装置的解剖固定方式(SuF 与 InF),长期随访时肾功能下降的情况。次要结局是住院时间(LOH)和进展为血液透析。多变量回归分析用于测试影响 LOH 的关联。
本研究共纳入 1130 例择期 EVAR。其中,670 例(59.3%)采用 SuF,460 例(40.7%)采用 InF。长期随访时间为 4.8±3.7 年,各组之间肌酐和估算肾小球滤过率(eGFR)的变化率无统计学意义(SuF 与 InF)。SuF 装置组的 LOH 更高(3.4±2.2 天 vs 2.3±1.0 天;P<0.001)。10 例慢性肾脏病患者在 EVAR 后 6.7±3.8 年进展为血液透析。在 Kaplan-Meier 分析中,SuF 慢性肾脏病患者更有可能进展为血液透析(P=0.039)。多变量回归分析显示,女性(Coef,2.4;95%置信区间 [CI],0.17-0.41;P=0.02)、SuF(Coef,9.5;95%CI,0.11-1.11;P<0.0001)和术中出血量大于 150 mL(Coef,15.4;95%CI,0.11-1.76;P<0.0001)是 LOH 延长的预测因素。
我们的三个地点、单一机构的数据表明,尽管接受择期 EVAR 的患者中 InF 组的起始 eGFR 统计学上较低,但装置固定类型在长期随访时并未影响肌酐和 eGFR。然而,在进行腹主动脉瘤修复时,对于那些已经存在肾功能障碍的患者,应谨慎操作。